HK Stock Market Move | CONCORD NE (00182) surged over 6% during trading, as its overseas AIDC integrated energy business opens up growth opportunities.
Xiehe New Energy (00182) surged over 6% during the session. As of the time of this report, it has risen 3.17% to HKD 0.325, with a trading volume of HKD 4.1854 million.
CONCORD NE (00182) rose by more than 6% during the trading session. As of the time of writing, it is up 3.17%, priced at HKD 0.325, with a trading volume of HKD 4.1854 million.
In news, CONCORD NE previously announced its interim results, reporting revenue of approximately 1.258 billion yuan and gross profit of approximately 584 million yuan for the first half of the year, with net profit attributable to shareholders around 100 million yuan. It is reported that the group is keenly seizing the huge electricity demand opportunities brought about by the rapid growth of global AI investments, and has proactively laid out its AIDC development and integrated energy solutions business in regions such as the United States, Southeast Asia, and Eastern Europe, with overall progress going smoothly.
Guoyuan International previously released a research report stating that in the medium to long term, the company's investment logic is gradually shifting from being a single domestic renewable operator to a multi-drive model of domestic existing operations + overseas PPA long-term agreements + development of data center business in the United States. The combination of overseas PPA long-term agreements and over 4GW project reserves in the United States, along with the development of the data center business, will open up new growth space for the next 2-3 years.
Related Articles

WING ON CO (00289) repurchased 13,000 shares at a cost of HKD 169,000 on September 2.

Hunan Warrant Pharmaceutical (688799.SH) subsidiary chemical raw material drug Elamomed has been approved for listing.
.png)
SSY GROUP (02005): The trustee has purchased a total of 1.2 million shares under the restricted share award plan.
WING ON CO (00289) repurchased 13,000 shares at a cost of HKD 169,000 on September 2.

Hunan Warrant Pharmaceutical (688799.SH) subsidiary chemical raw material drug Elamomed has been approved for listing.

SSY GROUP (02005): The trustee has purchased a total of 1.2 million shares under the restricted share award plan.
.png)
RECOMMEND





